UniProt P33981
Dual specificity protein kinase TTK (P33981)
Dual specificity protein kinase TTK (UniProt P33981), EC 2.7.12.1: 147 experimental structures on GenesisL1, 29 ligands bound, 22 pockets. Binding sites, pockets, druggability and 3D structures in GL1X.
- UniProt
- P33981
- Protein
- Dual specificity protein kinase TTK
- EC
- 2.7.12.1
- Experimental structures
- 147
- Predicted models
- 0
- Ligands
- 29
- Pockets
- 22 · 17 records with a druggable one
Structures
147 records of P33981 in the MolNFT archive: 147 experimental, 0 predicted.
| Entry | Title | Method | Chains | Ligands | Pockets |
|---|---|---|---|---|---|
| 2X9E | Human MPS1 in complex with nms-P715 | x-ray diffraction | A | — | — |
| 2X9E | Human MPS1 in complex with nms-P715 | x-ray diffraction | A | — | — |
| 2ZMC | Crystal structure of human mitotic checkpoint kinase Mps1 catalytic domain apo form | x-ray diffraction | A | — | — |
| 2ZMC | Crystal structure of human mitotic checkpoint kinase MPS1 catalytic domain apo form | x-ray diffraction | A | — | — |
| 2ZMD | Crystal structure of human Mps1 catalytic domain T686A mutant in complex with SP600125 inhibitor | x-ray diffraction | A | — | — |
| 2ZMD | Crystal structure of human MPS1 catalytic domain T686A mutant in complex with SP600125 inhibitor | x-ray diffraction | A | — | — |
| 3CEK | Crystal structure of human dual specificity protein kinase (TTK) | x-ray diffraction | A | — | — |
| 3CEK | Crystal structure of human dual specificity protein kinase (ttk) | x-ray diffraction | A | — | — |
| 3DBQ | Crystal structure of TTK kinase domain | x-ray diffraction | A | — | — |
| 3DBQ | Crystal structure of ttk kinase domain | x-ray diffraction | A | — | — |
| 3GFW | Crystal Structure of Human Dual Specificity Protein Kinase (TTK) in complex with a pyrolo-pyridin… | x-ray diffraction | A | — | — |
| 3GFW | Crystal structure of human dual specificity protein kinase (ttk) in complex with a pyrolo-pyridin… | x-ray diffraction | A | — | — |
| 3H9F | Crystal Structure of Human Dual Specificity Protein Kinase (TTK) in complex with a… | x-ray diffraction | A | — | — |
| 3H9F | Crystal structure of human dual specificity protein kinase (ttk) in complex with a… | x-ray diffraction | A | — | — |
| 3HMN | Crystal structure of human Mps1 catalytic domain in complex with ATP | x-ray diffraction | A | — | — |
| 3HMN | Crystal structure of human MPS1 catalytic domain in complex with ATP | x-ray diffraction | A | — | — |
| 3HMO | Crystal structure of human Mps1 catalytic domain in complex with the inhibitor staurosporine | x-ray diffraction | A | — | — |
| 3HMO | Crystal structure of human MPS1 catalytic domain in complex with the inhibitor staurosporine | x-ray diffraction | A | — | — |
| 3HMP | Crystal structure of human Mps1 catalytic domain in complex with a quinazolin ligand Compound 4 | x-ray diffraction | A | — | — |
| 3HMP | Crystal structure of human MPS1 catalytic domain in complex with a quinazolin ligand compound 4 | x-ray diffraction | A | — | — |
| 3VQU | CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH… | x-ray diffraction | A | — | — |
| 3VQU | Crystal structure of human MPS1 catalytic domain in complex with 4… | x-ray diffraction | A | — | — |
| 3W1F | Crystal structure of Human MPS1 catalytic domain in complex with… | x-ray diffraction | A | — | — |
| 3W1F | Crystal structure of human MPS1 catalytic domain in complex with 5-(5… | x-ray diffraction | A | — | — |
| 3WYX | CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH… | x-ray diffraction | A | — | — |
| 3WYX | Crystal structure of human MPS1 catalytic domain in complex with 6… | x-ray diffraction | A | — | — |
| 3WYY | CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH… | x-ray diffraction | A | — | — |
| 3WYY | Crystal structure of human MPS1 catalytic domain in complex with (E)… | x-ray diffraction | A | — | — |
| 3WZJ | CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH… | x-ray diffraction | A | — | — |
| 3WZJ | Crystal structure of human MPS1 catalytic domain in complex with 4-(6… | x-ray diffraction | A | — | — |
| 3WZK | CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH… | x-ray diffraction | A | — | — |
| 3WZK | Crystal structure of human MPS1 catalytic domain in complex with N… | x-ray diffraction | A | — | — |
| 4B94 | Crystal structure of human Mps1 TPR domain | x-ray diffraction | A, B, C, D | — | — |
| 4B94 | Crystal structure of human MPS1 tpr domain | x-ray diffraction | A, B, C, D | — | — |
| 4BHZ | Scaffold Focused Virtual Screening: Prospective Application to the Discovery of TTK Inhibitor | x-ray diffraction | A | — | — |
| 4BHZ | Scaffold focused virtual screening: prospective application to the discovery of ttk inhibitor | x-ray diffraction | A | — | — |
| 4BI0 | Scaffold Focused Virtual Screening: Prospective Application to the Discovery of TTK Inhibitor | x-ray diffraction | A | — | — |
| 4BI0 | Scaffold focused virtual screening: prospective application to the discovery of ttk inhibitor | x-ray diffraction | A | — | — |
| 4BI1 | Scaffold Focused Virtual Screening: Prospective Application to the Discovery of TTK Inhibitor | x-ray diffraction | A | — | — |
| 4BI1 | Scaffold focused virtual screening: prospective application to the discovery of ttk inhibitor | x-ray diffraction | A | — | — |
| 4BI2 | Scaffold Focused Virtual Screening: Prospective Application to the Discovery of TTK Inhibitor | x-ray diffraction | A | — | — |
| 4BI2 | Scaffold focused virtual screening: prospective application to the discovery of ttk inhibitor | x-ray diffraction | A | — | — |
| 4C4E | Structure-based design of orally bioavailable pyrrolopyridine inhibitors of the mitotic kinase MPS1 | x-ray diffraction | A | — | — |
| 4C4E | Structure-based design of orally bioavailable pyrrolopyridine inhibitors of the mitotic kinase MPS1 | x-ray diffraction | A | — | — |
| 4C4F | Structure-based design of orally bioavailable pyrrolopyridine inhibitors of the mitotic kinase MPS1 | x-ray diffraction | A | — | — |
| 4C4F | Structure-based design of orally bioavailable pyrrolopyridine inhibitors of the mitotic kinase MPS1 | x-ray diffraction | A | — | — |
| 4C4G | Structure-based design of orally bioavailable pyrrolopyridine inhibitors of the mitotic kinase MPS1 | x-ray diffraction | A | — | — |
| 4C4G | Structure-based design of orally bioavailable pyrrolopyridine inhibitors of the mitotic kinase MPS1 | x-ray diffraction | A | — | — |
| 4C4H | Structure-based design of orally bioavailable pyrrolopyridine inhibitors of the mitotic kinase MPS1 | x-ray diffraction | A | — | — |
| 4C4H | Structure-based design of orally bioavailable pyrrolopyridine inhibitors of the mitotic kinase MPS1 | x-ray diffraction | A | — | — |
| 4C4I | Structure-based design of orally bioavailable pyrrolopyridine inhibitors of the mitotic kinase MPS1 | x-ray diffraction | A | — | — |
| 4C4I | Structure-based design of orally bioavailable pyrrolopyridine inhibitors of the mitotic kinase MPS1 | x-ray diffraction | A | — | — |
| 4C4J | Structure-based design of orally bioavailable pyrrolopyridine inhibitors of the mitotic kinase MPS1 | x-ray diffraction | A | — | — |
| 4C4J | Structure-based design of orally bioavailable pyrrolopyridine inhibitors of the mitotic kinase MPS1 | x-ray diffraction | A | — | — |
| 4CV8 | MPS1 kinase with 3-aminopyridin-2-one inhibitors | x-ray diffraction | A | — | — |
| 4CV8 | MPS1 kinase with 3-aminopyridin-2-one inhibitors | x-ray diffraction | A | — | — |
| 4CV9 | MPS1 kinase with 3-aminopyridin-2-one inhibitors | x-ray diffraction | A | — | — |
| 4CV9 | MPS1 kinase with 3-aminopyridin-2-one inhibitors | x-ray diffraction | A | — | — |
| 4CVA | MPS1 kinase with 3-aminopyridin-2-one inhibitors | x-ray diffraction | A | — | — |
| 4CVA | MPS1 kinase with 3-aminopyridin-2-one inhibitors | x-ray diffraction | A | — | — |
87 records more on the page itself.
Ligands
- CL · Chloride ion · in 7 records
- 8QW · (2~{R})-2-(4-fluorophenyl)-~{N}-[4-[2-[(2-methoxy-4-methylsulfonyl-phenyl)amino]-[1,2,4]triazolo[1,5-a]pyridin-6-yl]phenyl]propanamide · in 4 records
- 8RH · Bay 1217389 · in 4 records
- NA · Sodium ion · in 4 records
- 8Q5 · ~{N}-cyclopropyl-4-[8-(2-methylpropylamino)imidazo[1,2-a]pyrazin-3-yl]benzamide · in 2 records
- 8QE · 4-[[4-azanyl-6-(~{tert}-butylamino)-5-cyano-pyridin-2-yl]amino]benzamide · in 2 records
- 8QZ · ~{N}-[3,5-diethyl-1-[2-[2-(2-methoxyethoxy) ethoxy]ethyl]pyrazol-4-yl]-2-[[2-methoxy-4-[4-(2-methoxyethanoyl)piperazin-1-yl]phenyl]amino]-5,6-dihydropyrimido[4,5-e]indolizine-7-carboxamide · in 2 records
- AD5 · N~6~-cyclohexyl-N~2~-(4-morpholin-4-ylphenyl)-9H-purine-2,6-diamine · in 2 records
- C5N · ~{N}-(2,6-diethylphenyl)-8-[[2-methoxy-4-(4-methylpiperazin-1-yl)phenyl]amino]-1-methyl-4,5-dihydropyrazolo[4,3-h]quinazoline-3-carboxamide · in 2 records
- CQ7 · 4-{[4-(cyclopentyloxy)-5-(2-methyl-1,3-benzoxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl]amino}-3-methoxy-N-methylbenzamide · in 2 records
- FMW · ~{N}8-(2,2-dimethylpropyl)-~{N}2-[2-ethoxy-4-(4-methyl-1,2,4-triazol-3-yl)phenyl]-6-methyl-pyrido[3,4-d]pyrimidine-2,8-diamine · in 2 records
- FZL · 4-(cyclohexylamino)-2-[[2-methoxy-4-(2-oxidanylidenepyrrolidin-1-yl)phenyl]amino]-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile · in 2 records
- N66 · ~{N}-(2,6-diethylphenyl)-2-[[2-methoxy-4-(4-methylpiperazin-1-yl)phenyl]amino]-5,6-dihydropyrimido[4,5-e]indolizine-7-carboxamide · in 2 records
- NN5 · [4-[[6-(3,5-dimethyl-4-oxidanyl-phenyl)-[1,2, 4]triazolo[1,5-a]pyridin-2-yl]amino]phenyl]-morpholin-4-yl-methanone · in 2 records
- O23 · N-cyclopropyl-4-{8-[(thiophen-2-ylmethyl) amino]imidazo[1,2-a]pyrazin-3-yl}benzamide · in 2 records
- PGF · 2,5,8,11-tetraoxatridecane · in 2 records
- SVE · N-(2,6-diethylphenyl)-1-methyl-8-({4-[(1-methylpiperidin-4-yl)carbamoyl]-2-(trifluoromethoxy) phenyl}amino)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide · in 2 records
- 0SQ · 1-[3-tert-butyl-1-(4-methylphenyl)-1H-pyrazol-5-yl]urea · in 1 record
- 5NW · N2-(2-Methoxy-4-(1-methyl-1H-pyrazol-4-yl)phenyl)-N8-neopentylpyrido[3,4-d]pyrimidine-2,8-diamine · in 1 record
- 5O1 · ~{N}8-cyclohexyl-~{N}2-[2-methoxy-4-(1-methylpyrazol-4-yl)phenyl]pyrido[3,4-d]pyrimidine-2,8-diamine · in 1 record
- 5O7 · ~{N}-(2,4-dimethoxyphenyl)-8-(1-methylpyrazol-4-yl)pyrido[3,4-d]pyrimidin-2-amine · in 1 record
- 5OE · ~{N}-[2-methoxy-4-(1-methylpyrazol-4-yl)phenyl]-8-(1-methylpyrazol-4-yl)pyrido[3,4-d]pyrimidin-2-amine · in 1 record
- 5OQ · ~{N}-(2,4-dimethoxyphenyl)-5-(1-methylpyrazol-4-yl)isoquinolin-3-amine · in 1 record
- 8PT · ~{N}6-cyclohexyl-~{N}2-(2-methyl-4-morpholin-4-yl-phenyl)-7~{H}-purine-2,6-diamine · in 1 record
- FZF · 4-(cyclohexylamino)-2-[(2-methoxy-4-morpholin-4-ylcarbonyl-phenyl)amino]-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile · in 1 record
- FZR · 4-(cyclohexylamino)-2-[(1-methylpyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile · in 1 record
- G0U · 4-(cyclopentylmethylamino)-2-[[2-methoxy-4-(2-oxidanylidenepyrrolidin-1-yl)phenyl]amino]-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile · in 1 record
- G5C · 2-[[2-methoxy-4-(2-oxidanylidenepyrrolidin-1-yl) phenyl]amino]-4-(methylamino)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile · in 1 record
- KE7 · 4-({5-chloro-4-[(cis-4-hydroxy-4-methylcyclohexyl)oxy]-7H-pyrrolo[2,3-d]pyrimidin-2-yl}amino)-N,N-dimethyl-3-{[(2R)-1,1,1-trifluoropropan-2-yl]oxy}benzamide · in 1 record
Elsewhere
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.